TYMS and colorectal carcinoma: The results of the present study suggest a benefit from combining vorinostat with capecitabine in CRC, indicating that the modulation of TS and TP expression by vorinostat may explain the synergistic interaction between these two drugs observed both in vitro and in vivo.